Fig. 3From: Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibodyBaseline (pre-treatment) expression of PD-L1 as a percentage of total PBMC. In 28 patients prior to avelumab therapy, expression of PD-L1 was measured by flow cytometry for nine classic subsets as a percentage of total PBMC, with graphs displaying median and interquartile rangeBack to article page